1. Perhimpunan Dokter Paru Indonesia (PDPI).

PPOK (Penyakit Paru Obstruksi Kronik), pedoman

praktis diagnosis dan penatalaksanaan di Indonesia; 2010.
2. NHLBI / WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy
for diagnosis, management and prevention of chronic obstructive pulmonary disease. Am J Respir
Crit Care Med.163.2001. 1256-76
3. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 343. 2000. 269-80.
4. Chambers, H.F., 2006.Pulmonary Disease. Current Medical Diagnosis and Treatment (45th
ed), 1425-1426.

5. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2013. Global Strategy for
Diagnosis, Management and Pre vention of Chronic Obstructive Pulmonary Disease.
Available at http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf.
USA.
6. American Thoracic Society.Standards for Diagnosis and care of patient with COPD. Am J
Respir Crit Care Med 1995;152:S77-120
7. Chan-Yeung M, Ait Khaled N, White N, Ip MS, and Tan WC, The Burden and Impact of
COPD in Asia and Africa, Int J Tuberc Lung Dis, 2004; 8; p.2-14
8. Charoentratanakul S. Impact of CPD in the Asia-Pasific Region. Presented at the 7th ASPR
Congress. Taipei. October. 2002
9. Tobias Welte. Acute exacerbation in COPD: we must do more. Eur Respir J 2016; 47: 14–15
10. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of
patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004 Jun;
23(6):932–946.
11. Quality-Based Procedures: Clinical Handbook for Chronic Obstructive Pulmonary Disease
qbp_copd.pdf. Available at: http://health.gov.on.ca/en/pro/programs/ecfa/docs/qbp_copd.pdf.
12. Alsaggaf Hood, dkk. 2004. Buku Ajar Ilmu Penyakit Paru. Bagian Ilmu Penyakit
Paru FK Unair. Surabaya.
13. Glaxo, Smith, Kline. 2011. COPD Assessment Test and CAT . Available at
http://www.hampshirelpc.org.uk/webfm_send/3109. USA.
14. Chambers, H.F., 2006.Pulmonary Disease. Current Medical Diagnosis and Treatment (45th
ed), 1425-1426.
15. Communicable Disease Surveillance and Response Vaccines and Biological, 2007,
Background Document: The Diagnosis, Treatmen, and Prevention of COPD, WHO,
Switzerland.
16. Communicable Disease Surveillance and Response Vaccines and Biological, 2007,
Background Document: The Diagnosis, Treatmen, and Prevention of COPD, WHO,
Switzerland
17. Global Initiative for Chronic Obstructive Lung Disease, 2007. Pocket Guide to COPD
Diagnosis, Management, and Prevention Update 2007.
http://www.golcopd.og/download.asp?intId=446
18. Barnes JP, Hansel TT, 2003. An Atlas of Chronic Obstruktive Pulmonary Disease COPD.
London : The Parthenon Publishing Group Hlm 3-5.

19. Aditama TY, 2001. Penyakit Akibat Merokok. Dalam Masalah Perokok. Dan
Penanggulangannya. Jakarta: Yayasan Penerbitan Ikatan Dokter Indonesia.
20. Teramoto S, 2007. COPD Phatogenesis from the Viewpoint of Risk Factors. Tokyo: Internal
Medicine.

21. Long term effect og budesonide or nedocromil . N Engl J Med. 0ct 12 2000;343(15):105463
22. Hendri Nofa, Yusrizal Chan, Masrul Basyar, Oea Khairsyaf. Azithromycin Towards COPD
Assesment Test (CAT) for Stable Chronic Obstructive Pulmonary Disease. J Respir Indo.
2015; 35: 46-50)
23. Uzun S, Jamin RS, Kluytman JA, Mulder PG, Van’t Veer NE, Ermens AA, Pelle AJ,
Hoogsteden HC, Aerts JG, Van der Eerden MM. Azitromycin maintenance treatment in
patients with frequent exacerbations of chronic obstructive pulmonary disease (colombus): a
randomized, double blind, placebo-controlled trial. Lancet Respi Med. 2014 Apr 15. (14)
70019-0.
24.
25.
26.